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In this paper further evidence of the important role of the chlamydial plasmid in virulence is provided. In both the respiratory
and urogenital tract sites, the plasmid-containing version of Chlamydia trachomatis was more virulent than the non-plasmid
strain, when analysed in the mouse model. While this has previously been shown with the mouse strain of Chlamydia, this is
the first report showing similar virulence characteristics of the human C. trachomatis strains.
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Abstract
We hypothesized that the plasmid of urogenital isolates of Chlamydia trachomatis
would modulate infectivity and virulence in a mouse model. To test this hypothesis,
we infected female mice in the respiratory or urogenital tract with graded doses of
a human urogenital isolate of C. trachomatis, serovar F, possessing the cognate
plasmid. For comparison, we inoculated mice with a plasmid-free serovar F isolate.
Following urogenital inoculation, the plasmid-free isolate displayed significantly
reduced infectivity compared with the wild-type strain with the latter yielding a
17-fold lower infectious dose to yield 50% infection. When inoculated via the
respiratory tract, the plasmid-free isolate exhibited reduced infectivity and
virulence (as measured by weight change) when compared to the wild-type
isolate. Further, differences in infectivity, but not in virulence were observed in a
C. trachomatis, serovar E isolate with a deletion within the plasmid coding
sequence 1 when compared to a serovar E isolate with no mutations in the
plasmid. We conclude that plasmid loss reduces virulence and infectivity in this
mouse model. These findings further support a role for the chlamydial plasmid in
infectivity and virulence in vivo.
Introduction
Chlamydial plasmids are all small [c. 7.5 kb, 8 coding
sequences (CDSs)], highly conserved (< 1% variation within
the species), nonconjugative, and nonintegrative, and their
role in C. trachomatis pathobiology remains to be fully
explored (Thomas et al., 1997; Seth-Smith et al., 2009). A
long-standing observation has been that naturally occurring
plasmid-deficient C. trachomatis are exceedingly rare,
implying a significant, but noncritical role in fitness and
transmission in vivo.
In vivo studies of the C. trachomatis plasmid have only
recently begun and have thus far employed either the
plasmid-free human C. trachomatis lymphogranuloma
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venereum (LGV, serovar L2, strain 25667R) or a plas-
mid-free trachoma isolate (serovar A, strain A2497P-) where
the plasmid has been cured by novobiocin treatment
(Carlson et al., 2008; Olivares-Zavaleta et al., 2010; Kari
et al., 2011). In ocular infection of lower primates, plas-
mid-free C. trachomatis strain A2497P- was found to infect,
but was significantly attenuated for shedding of viable
chlamydiae and inducing inflammatory responses (Kari
et al., 2011). In mice inoculated in the lower urogenital tract
with a naturally occurring plasmid-free isolate of C. tracho-
matis LGV, serovar L2, reduced infectivity was seen
(Carlson et al., 2008; Olivares-Zavaleta et al., 2010). It is
important to note that in these studies, the plasmid-free
C. trachomatis strains, while attenuated for infectivity in the
mouse urogenital tract (L2, 25667R) or in primate eyes (A,
A2497P-), nonetheless were able to elicit immune responses
that protected against virulent and fully infectious matched
plasmid-containing wild-type strains. This has led some to
assert that plasmid-free strains may be effective attenuated
vaccines (Olivares-Zavaleta et al., 2010; Kari et al., 2011).
Similar results have been reported in the mouse model of
urogenital infection with the mouse pathogen, C. muridarum
(O’Connell et al., 2007). It is also important to note that none
of the aforementioned studies have utilized urogenital
isolates ofC. trachomatis, and thus, it could be hypothesized
that the plasmid of urogenital isolates possesses different
qualities and would behave differently in an animal model
when compared to the others thus far examined.
In the present study, we have assessed for the first time
the infectivity and virulence of naturally occurring plas-
mid-free and a cocirculating plasmid-containing (hereafter,
wild-type) urogenital isolates of C. trachomatis, serovar F,
as well as the Swedish new variant C. trachomatis (nvCT;
serovar E, with a mutation in CDS1) in a mouse model of
urogenital or respiratory infection.
Materials and methods
Chlamydia trachomatis strains used in this study
Four urogenital isolates of C. trachomatis were used in this
study; C. trachomatis Sweden 3 and 4 (hereafter, E/SW3
and F/SW4, respectively) were isolated in Malm€o, Southern
Sweden, in 2002 and are serovar E and F, respectively,
representing plasmid-containing wild-type cervical isolates
(Seth-Smith et al., 2009). Chlamydia trachomatis Sweden 2
(E/SW2), representing the Swedish nvCT (plasmid-contain-
ing serovar E, with a 377-base pair deletion in CDS1), was
isolated from a male urethra in Malm€o in 2006 (Seth-Smith
et al., 2009; Unemo et al., 2010). Chlamydia trachomatis
Sweden, serovar F, plasmid-free (F/SWFP) is a cervical
isolate from Malm€o, Sweden, in 1995 (Persson et al., 1996;
Wang et al., 2012). All isolates were cultured only in McCoy
cells with minimal passage number.
Genome sequencing
Extraction of DNA was performed on strain F/SWFP as
previously described (Seth-Smith et al., 2009). DNA was
sequenced on the Illumina GAII platform using 54-bp
paired-end reads, resulting in a mean genome coverage of
1527 9. A subset of Illumina reads was assembled using
Velvet, version 1.0.12 (Zerbino & Birney, 2008), producing
contiguous nucleotide sequences (contigs), which were
scaffolded against the genome of strain F/SW4 (EMBL
accession no. HE601804) (Harris et al., 2012), using ABACAS
(Assefa et al., 2009). The two rRNA operons assembled into
a single contigs, which were manually corrected, as were
contig boundaries where possible. Manual insertion of
capillary-sequenced hctB and tarp gene sequences was
followed by self-mapping with all the sequence reads to
confirm the assembled sequence and resulted in an
improved high-quality draft sequence (Chain et al., 2009).
After this process, the assembly of strain F/SWFP com-
prised three contigs. Annotated features were transferred
from the closely related strain F/SW4 using annota-
tions_update.pl (https://github.com/sanger-pathogens/anno-
tations_update) on the basis of BLASTN similarity using the
default cut-off of 90% and manually curated using Artemis
(Rutherford et al., 2000). Mapping of sequence data to
reference genomes was carried out using SMALT (http://www.
sanger.ac.uk/resources/software/smalt/). Genome compari-
sons were visualized using the Artemis Comparison Tool
(ACT) (Carver et al., 2005). The genome sequence and
annotation have been deposited in the EMBL database
under the accession number HE605380, and the read data
are in SRA under the accession number ERS001400.
Mice
We selected an outbred strain of mice (Swiss Webster, SW)
for these experiments. Five- to six-week-old female SW
mice were obtained from Harlan Sprague Dawley (India-
napolis, IN) and housed with commercial rodent chow and
water ad libitum with a 12 : 12 light/dark cycle. All mice were
subject to a 7–10-day facility acclimation period prior to
inclusion in the study. All studies were approved by the
Midwestern University Institute Animal Care and Use Com-
mittee (MWU File # 1726).
Infection of mice and assessment of infection by
culture
For urogenital infection, mice were pretreated with 2.5 mg of
medroxyprogesterone acetate (DepoProvera, P4; Green-
stone LLC, Peapack, New Jersey) and 7 days later were
inoculated intravaginally (i.vag.) with log10-graded doses of
McCoy cell-grown C. trachomatis as described elsewhere
(Ramsey et al., 1999). To verify and track urogenital
infection, cervical–vaginal swabs were collected in all mice
at day 4, 7, 10, and 14 postinfection in each experiment.
Chlamydia trachomatis was isolated inclusions visualized by
indirect immunofluorescence and quantified as inclu-
sion-forming units (IFU) in HeLa 229 cultures as previously
described (Ramsey et al., 1999).
For respiratory infection, mice were anesthetized via
inhalation of 4–5% isoflurane and placed in dorsal recum-
bency, and log10-graded doses of the strains were inoculated
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dropwise into the nasal nares exactly as described else-
where (Ramsey et al., 2009). Mice were weighed daily, and
weight gain or loss from baseline weight was recorded as a
measure of morbidity. It should be noted that none of the
inoculated mice exhibited any overt morbidity from the
infection, and there were no mortalities following infection.
Hence, lethal dose that induces mortality in 50% of the
inoculated mice (LD50) was not determined.
Antibody responses
For both urogenital and respiratory inoculations, we have
found it useful to assess seroconversion postinfection as a
means to assess infection at levels below the level of
detection of our culture methods (e.g. at low dose infection).
For this purpose, blood was collected at day 0, just prior to
infection, and 35 or more days postinoculation, and total
plasma anti- C. trachomatis immunoglobulin G (IgG) levels
were determined by enzyme-linked immunosorbent assay
(ELISA) as described previously (Ramsey et al., 1989,
2009). An antibody titer ≥ 40 was considered positive for
the determination of seroconversion. Immunoglobulin G
antibody responses were also compared as a measure of
elicitation of adaptive immunity and as an indirect measure of
the degree of infection (greater infectious burden correlating
to a greater antibody response). For quantitative comparison
of antibody responses, titers were converted to log10, and the
arithmetic mean of all seropositive animals was determined
as described elsewhere (Ramsey et al., 1988).
Statistics
Infection course data, as assessed by shedding of viable
organisms (lower genital tract) and weight change over time
(respiratory tract), were compared by analysis of the
variance (ANOVA, treatment group, days) with repeated
measures. Results for ELISA and IFU counts at individual
time points were compared using a two-tailed unpaired
t-test. The incidence of viable chlamydial shedding and
seroconversion was assessed using Fisher’s exact test.
Infectious dose that yielded a 50% of mice infected (ID50)
was estimated by the method of Read and Muench (Reed &
Muench, 1938).
Results
Plasmid deficiency in a C. trachomatis urogenital
isolate correlates with reduced infectivity in the mouse
urogenital tract
In our first experiment, we intravaginally inoculated groups
of 10 mice with log10-graded doses of either F/SW4 or
F/SWFP C. trachomatis and monitored outcomes of
infection. Table 1 shows the results of the study. In both
wild-type and plasmid-free inoculated groups, low numbers
of viable organisms were shed intermittently through day 10
postinfection, but no animals in either group remained
culture positive by day 14. The wild-type F/SW4 isolate had
an estimated ID50 of 3.2 9 10
5 IFU. We were unable to
infect 50% of the mice with the plasmid-free isolate using
our highest dose of 106 IFU – despite a second experimental
attempt using 7 additional mice (data compiled in Table 1).
Thus, we assert only that the ID50 of the F/SWFP isolate
(as determined by culture) to be in excess of 106 IFU. In
addition, at the 106 IFU dose, the day 4 and day 7, IFU
isolation attempts indicated a greater infectious burden in
animals inoculated with the F/SW4 isolate (P = 0.01 and
P = 0.03, respectively, by two-tailed unpaired t-test). As we
Table 1 ID50 determination with Serovar F plasmid variant strains in urogenital tract infection
Dose
F/SW4 (plasmid +) F/SWFP (plasmid )
P-value*Culture +†
Seroconversion‡
(mean Ab titer  SD) Culture +†
Seroconversion‡
(mean Ab titer  SD)
103 0/10 5/10
(1.08  1.0)
0/10 2/10
(0.76  1.1)
0.35
0.49
104 0/10 6/10
(1.4  1.4)
0/10 5/10
(0.8  0.87)
1.0
0.3
105 3/10
(40–484)
9/10
(2.3  0.8)
0/9 5/9
(1.93  0.64)
0.22/0.15
0.32
106 7/10
(16–2705)
10/10
(2.51  0.8)
8/17
(4–192)
12/17
(1.8  0.48)
0.42/0.12
0.07
ID50
§ 316 277 2956 > 106 50 133
*P values were determined by comparing strains at each dose for either the ratio of culture positive to culture negative or the ratio of seroconverters by
a two-tailed Fisher’s exact test. Geometric mean antibody titers were compared by a two-tailed Student’s t-test.
†Number of mice culture positive of the total mice inoculated at the given dose with either F/SW4 or F/SWFP strains. Culture detection of infection
was attempted on swabs collected at 4, 7, and 10 days postinfection. Range of IFU counts (considering all mice and time points postinfection) is
shown in parentheses.
‡Numberofmiceof the total testeddisplayingseroconversionforplasmaIgGantibody(day35postinfection)againstserovarFantigen.Themeangeometric
antibody titer  the standard deviation of mice that seroconverted following inoculation is provided in parentheses (titers ranged from 40 to 5120).
§ID50 is the calculated dose that will achieve 50% infection rate. Data are given in IFUs as calculated by the method of Reed and Muench (Reed &
Muench, 1938).
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have previously observed, seroconversion provides a more
sensitive method of determining infection below the level of
detection of culture (Ramsey et al., 2009). Thus, we were
able to use seroconversion to achieve an ID50 for both
groups with the plasmid-free isolate also displaying reduced
infectivity (ID50 ~ 17-fold higher) by this measure. Antibody
titers were not statistically different between the two groups.
Cumulatively, these data show that while the mouse
urogenital tract is not a highly permissive environment for
urogenital isolates of C. trachomatis, plasmid deficiency
renders the pathogen even less fit when compared to a
wild-type serovar-matched isolate in this model.
Plasmid deficiency in a C. trachomatis urogenital
isolate correlates with reduced infectivity and morbidity
in the mouse respiratory tract
Unlike C. muridarum, which naturally ascends into the upper
urogenital tract and induces pathogenic host responses,
C. trachomatis isolates are less likely to ascend and are less
virulent for the urogenital tract in the mouse model. Induction
of chronic oviduct damage by C. trachomatis in the mouse
requires direct inoculation into the upper genital tract of mice
via surgical exposure of the ovarian bursa or oviducts
(Tuffrey et al., 1986a, b). However, weight change following
respiratory infection is a common means to generally assess
human pathogen virulence in rodent models (Fox, et al. Ed.,
2007) and has been used to assess chlamydial virulence in
the mouse (Ramsey et al., 2009; He et al., 2011). For this
reason, we sought to assess the in vivo infectivity and
morbidity of F/SWFP and wild-type F/SW4 C. trachomatis
via intranasal inoculation of mice.
Table 2 shows that statistically significant differences in
infectivity were observed between the groups at the lowest
dose where 4 of 10 animals seroconverted when inoculated
with 103 IFU of the F/SWFP (estimated ID50 = 1292 IFU),
but all 10 animals seroconverted when inoculated with
plasmid-carrying F/SW4 (ID50 < 1000) at the same dose.
Statistical significance was also achieved when assessing
differences in antibody levels in the groups inoculated with
106 IFU of the wild-type strain evoking higher antibody levels
in those that seroconverted. While not consistent across all
doses, these data indicate enhanced infectivity in the
presence of the plasmid.
Figure 1 shows that following an initial loss in weight in all
groups (likely due to the stress of anesthesia and dosing
procedures), all groups gradually recovered initial body
weight and began to gain weight above baseline day 0
weights. Overall, a distinct trend was observed in the 103,
104, and 105 groups where mice inoculated with the
wild-type F/SW4 strain gained less weight over time than
those inoculated with identical doses of the F/SWFP
isolate. While this did not achieve statistical significance at
the 103 dose – likely due to low number of the F/SWFP
isolate-infected mice with only 4 mice in this group
seroconverting – the difference in weight gain in the 104
and 105 groups was highly significant. This indicates that the
F/SW4 isolate caused greater morbidity than did the
plasmid-deficient F/SWFP isolate. Interestingly, at the
highest intranasal dose (106), no differences in weight gain
over time between the wild-type and plasmid-free infected
groups were observed, although both groups gained less
weight than identical groups at lower doses. This suggests
that higher doses compensate for the loss of the plasmid
when comparing weight changes observed in the lower dose
groups. Lastly, it is notable that neither the plasmid-free
C. trachomatis F/SWFP nor the F/SW4 isolate induced
any mortalities over the 21-day monitoring period, indicating
low virulence of human urogenital C. trachomatis isolates in
this nonhuman host.
Table 2 ID50 determination with Serovar F plasmid variants in respiratory tract infection
Dose
F/SW4 (plasmid +) F/SWFP (plasmid )
P-value*Mortality†
Seroconversion‡
(mean Ab titer  SD) Mortality
Seroconversion
(mean Ab titer  SD)
103 0/10 10/10
(1.99  0.57)
0/10 4/10
(1.96  0.7)
0.03
0.93
104 0/10 10/10
(2.77  0.58)
0/10 10/10
(2.75  0.71)
1.0
0.5
105 0/10 10/10
(3.51  0.54)
0/10 10/10
(3.2  0.38)
1.0
0.17
106 0/10 10/10
(3.2  0.35)
0/10 10/10
(3.62  0.45)
1.0
0.03
ID50
§ ND < 1000 ND 1292
*P values were determined by comparing strains at each dose for either the ratio of seroconverters by a two-tailed Fisher’s exact test or geometric
mean antibody titers by a two-tailed Student’s t-test.
†Number of moribund mice of the total inoculated at the given dose with either F/SW4 strain or F/SWFP strain through a c. 20-day monitoring period.
‡Number of mice of the total tested displaying seroconversion for plasma IgG antibody (day 35 postinfection) against serovar F (SW4) antigen. Themean
geometric antibody titer  the standard deviation of mice that seroconverted following inoculation is provided in parentheses (titer range = 20–10 240).
§Calculated infectious dose that will achieve 50% infection rate (seroconversion) as calculated by themethod of Reed andMuench (Reed &Muench, 1938).
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A naturally occurring plasmid mutation in CDS1 results
in reduced infectivity without affecting virulence
In 2006, the Swedish nvCT that contained a 377-bp deletion
mutation in CDS1 was isolated in Sweden (Ripa & Nilsson,
2006). One serovar E isolate from this outbreak, Sweden 2
(E/SW2), like all nvCT strains, was undetectable by two of
the major nucleic acid-based diagnostic test targeting
CDS1. Because this mutant pathogen amplified rapidly in
the Swedish population, it was hypothesized that evolution-
ary pressures exerted by screen-and-treat public health
programs using the diagnostic test had selected the mutant.
However, it could not be ruled out that the degree of spread
could also have been attributed to selective biological fitness
advantages incurred as a result of plasmid deficiency. This
is why, we sought to test the hypothesis that mutation in the
plasmid CDS1 observed in E/SW2 enhanced in vivo fitness
when compared to a closely matched and cocirculating
serovar E (E/SW3) isolate that carried a wild-type intact
plasmid.
Table 3 shows the results of comparing infectivity of these
two isolates in the urogenital tract following intravaginal
inoculation. When assessed by culture, neither the wild-type
nor plasmid mutant showed a difference in ID50 or chla-
mydial shedding. However, there were slight differences in
the rate of seroconversion with c. twofold higher ID50 in the
nvCT isolate E/SW2 and significantly increased antibody
responses in the E/SW3 isolate when compared to the
mutant at the 105 and 106 doses. Table 4 shows the results
of comparing infectivity of the E/SW2 and E/SW3 isolates in
the respiratory tract following intranasal inoculation. As seen
with urogenital infection, the ID50 was increased in the
plasmid mutants over the wild-type isolate. However, an
accurate ID50 for the E/SW3 infected group could not be
obtained because, even at the lowest dose of 103 IFU, all
mice seroconverted, whereas at the identical dose of the
(a) (b)
(c) (d)
Fig. 1 Weight change following intranasal inoculation of mice with plasmid-deficient or plasmid-sufficient isolates of Chlamydia trachomatis, serovar
F. Mice were administered graded doses of C. trachomatis serovar F urogenital isolates either F/SWFP-(plasmid-deficient) or F/SW4
(plasmid-sufficient). (a) 103 IFU; (b) 104 IFU; (c) 105 IFU; and (d) 106 IFU. P values shown are result of two-way, repeated-measures ANOVA. Each
data point is the mean for all infected animals in that group (as indicated by seroconversion). For all groups, N = 10 with the exception of the group
administered 103 IFU of SWFP. In this case, only the results of the 4 mice that seroconverted following inoculation are shown.
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plasmid mutant E/SW2, only 4 of 10 seroconverted. Addi-
tionally, as seen with urogenital infection, intranasal infec-
tion with the wild-type isolate stimulated higher antibody
responses at the 104 and 106 doses, while the difference
noted at the 105 dose did not quite achieve statistical
significance. Weight change post-intra-nasal infection was
also monitored in this group, but there were no remarkable
differences in weight loss or reduction in weight gain over
time as was seen following intranasal infection with the
mutant-isolate in the previous experiments (data not
shown). From these data, we conclude the mutation that
occurred in the E/SW2 isolate had a modest effect on in vivo
fitness of the isolate in the mouse host, and this effect was
to reduce fitness, not to enhance it.
Genome comparisons
The genomes of nvCT serovar E strains E/SW2 and
contemporaneous E/SW3 and E/SW4 have been described
and published elsewhere (Harris et al., 2012). When
Table 3 ID50 determination with Serovar E plasmid variant strains in urogenital tract infection
Dose
E/SW3 (plasmid +) E/SW2 (plasmid mutant)
P-value*
Culture†
(range of IFU)
Seroconversion‡
(mean Ab titer  SD)
Culture†
(range of IFU)
Seroconversion‡
(mean Ab titer  SD)
103 0/10 7/10
(2.2  0.65)
0/10 6/10
(2.2  0.6)
1.0
1.0
104 0/10 8/10
(1.7  1.0)
0/10 7/10
(2.2  0.3)
1.0
0.75
105 5/10
(30–520)
10/10
(2.32  0.6)
5/10
(30–160)
9/10
(1.7  0.66)
1.0
0.006
106 10/10
(200–5260)
10/10
(2.96  0.61)
10/10
(30–4070)
10/10
(2.32  0.67)
1.0
0.04
ID50
§ 100 000 718 100 000 1631
*P values were determined by comparing strains at each dose for either the ratio of culture positive to culture negative or the ratio of seroconverters by
a two-tailed Fisher’s exact test. Geometric mean antibody titers were compared by a two-sided Student’s t-test.
†Number of mice culture positive of the total mice inoculated at the given dose with either E/SW3 or E/SW2 strain. Culture detection of infection was
attempted on swabs collected at 4, 7, and 10 days postinfection. Range of IFU counts (considering all mice and time points postinfection) are shown in
parentheses.
‡Number of mice of the total tested displaying seroconversion for plasma IgG antibody (day 35 postinfection) against serovar E antigen. The mean
geometric antibody titer  the standard deviation ofmice that seroconverted following inoculation is provided in parentheses (titers ranged from40 to 5120).
§ID50 is the calculated dose that will achieve 50% infection rate. Data are given in IFUs as calculated by the method of Reed and Muench (Reed &
Muench, 1938).
Table 4 ID50 determination with Serovar E plasmid variant strains in respiratory tract infection
Dose
E/SW3 (plasmid +) E/SW2 (plasmid mutant)
P-value*Mortality†
Seroconversion‡
(mean Ab titer  SD) Mortality†
Seroconversion‡
(mean Ab titer  SD)
103 0/10 10/10
(2.2  0.48)
0/10 4/10
(2.8  1.0)
0.02
0.85
104 0/10 10/10
(3.3  0.48)
0/10 9/10
(2.2  0.58)
1.0
0.0008
105 0/10 10/10
(3.65  0.28)
0/10 10/10
(3.38  0.39)
1.0
0.09
106 0/10 10/10
(3.77  0.31)
0/10 10/10
(3.5  0.25)
1.0
0.046
ID50
§ < 1000 1743
*P values were determined by comparing strains at each dose for either the ratio of seroconverters by a two-tailed Fisher’s exact test or geometric
mean antibody titers by a two-tailed Student’s t-test.
†Number of moribund mice of the total inoculated at the given dose with either E/SW3 (plasmid-intact parental) strain or E/SW2 (plasmid mutant) strain
through a c. 20-day monitoring period.
‡Number of mice of the total tested displaying seroconversion for plasma IgG antibody (day 35 postinfection) against serovar E antigen. The mean
geometric antibody titer  the standard deviation of mice that seroconverted following inoculation is provided in parentheses (titer range = 40–10 240).
§Calculated infectious dose that will achieve 50% infection rate (seroconversion) as calculated by themethod of Reed andMuench (Reed &Muench, 1938).
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comparing nvCT strain E/SW2 and E/SW3, we previously
showed that there were a total of 229 SNPs separating
these two strains, 158 of which are found in a 30-kb region
spanning genes SW2 1391 (CTL-393) to SW2 1601
(CTL-417) (Harris et al., 2012). This SNP-dense region
was shown to be a region of recombination and encom-
passes genes located alongside the plasticity zone or PZ.
The PZ is a region of high variation both in terms of
recombination and functional gene loss.
As a comparator to F/SW4 for our in vivo studies, the
genome of strain F/SWFP was sequenced and assem-
bled. The F/SWFP genome was 1 042 732 bp in length
with no evidence of plasmid, either as an extrachromosomal
element or integrated into the chromosome. There were no
wholesale gene gains or losses. In addition to the lack of
plasmid, the genome of F/SWFP also differed from that of
strain F/SW4 by 178 SNPs listed in Supporting Information,
Table S2. The majority of these were found clustered in two
regions likely to be explained by recombination. 31 SNPs
between bases 167 543 and 171 733 of the F/SW4
genome, 26 being located within gene F/SW-41481 pre-
dicted to encode an integral membrane protein and a single
SNP in F/SW-41491 – a FAD-dependent monooxygenase.
Notably, this region overlaps with the putative recombined
regions in nvCT serovar E strain E/SW2 (Harris et al.,
2012). The second region of high SNP density contained 92
SNPs found between bases 710 211 and 725 729, affecting
a 15-kb region encompassing 14 genes, F/SW4 6341–6471.
The affected genes fall into several functional classes
including core functions as well as more those orthologous
to putative virulence genes. One example is the mviN gene,
which has been shown to play a role in virulence in
Francisella tularensis infections in mice (Ulland et al.,
2010). Analysis of the pseudogenes within F/SWFP did
not indicate any unique pseudogenes compared with other
sequenced strains of serotype E and F (F/SW4, E/SW2, E/
SW3; Table S3).
Discussion
For many years, the chlamydial plasmid was referred to as
the ‘cryptic plasmid of Chlamydia’. This descriptor refer-
enced the unknown function of the plasmid that is carried by
nearly all C. trachomatis ocular and urogenital isolates.
However, it is arguably no longer accurate to refer it as
‘cryptic’. For example, we now know the criticality of the
plasmid in eliciting pathogenic immune responses in several
model systems as well as in conveying certain key in vitro
phenotypes (e.g. glycogen accumulation) and in controlling
the expression of certain genes on the Chlamydia chromo-
some. Overall, studies of infection with both wild-type and
plasmid-free C. trachomatis and C. muridarum strains in
mouse urogenital infection indicate that the plasmid modu-
lates infectivity and may be essential for pathogenic immune
responses (O’Connell et al., 2007; Carlson et al., 2008;
Olivares-Zavaleta et al., 2010; Russell et al., 2011). It is all
but certain that either C. muridarum plasmid gene products
or products of plasmid responsive loci on the bacterial
chromosome engage Toll-like receptor-2 (TLR-2) causing
deleterious responses in mouse urogenital infections with
C. muridarum (O’Connell et al., 2011). Similarly, in ocular
infection of lower primates, plasmid-free C. trachomatis was
found to infect, but was significantly attenuated for inducing
inflammatory responses (Kari et al., 2011). Although the
plasmid seems essential for certain measures of pathoge-
nicity in mouse urogenital tract infection with C. muridarum,
in the mouse respiratory tract, deficiency of the plasmid in
C. muridarum seems to have opposite effects, with
increased pathological responses when the plasmid is not
present (He et al., 2011). Likewise, it is important to note
that plasmid-free C. psittaci intraperitoneal (i.p.) infections
of mice or plasmid-free C. caviae urogenital infection in
guinea pigs results in different outcomes (Miyairi et al.,
2011; Frazer et al., 2012). In both models, the plasmid was
dispensable regarding attenuation of virulence, and in the
C. psittaci i.p. mouse model, a handful of chromosomal
single nucleotide polymorphisms was left to account for
virulence differences between wild-type and plasmid-free
strains (Miyairi et al., 2011). Interestingly, the important
human and zoonotic pathogen, C. pneumoniae, does not
normally carry a plasmid nor does its chromosome contain
any genes related to chlamydial plasmids (Thomas et al.,
1997). It would be convenient if all observations of chla-
mydial strains and infections in various models were
consistent, but one must remember that these differences
likely reflect different chlamydial species and/or infection at
a different anatomical site and thus adaption of the patho-
gen and its plasmid to each host and anatomical niche.
Based on these observations, one could readily assert that
each Chlamydia–host interaction is unique, and the role of
the plasmid in these interactions is concomitantly variable.
In the present study, we have specifically assessed for the
first time, the infectivity and virulence of naturally occurring
wild-type and plasmid-free urogenital isolates of C. tracho-
matis, serovar F. Mice inoculated with a plasmid-free
urogenital isolate of C. trachomatis displayed higher ID50
by both urogenital and respiratory routes of inoculation and
reduced weight gain over time. There were no wholesale
gene deletions or substitutions in these isolates although
several SNPs were observed – especially in selected
regions of the chromosome. While we cannot rule out a
contributory role of genes affected by SNPs in these
isolates, our data are consistent overall with studies in other
model systems that support a critical role for the plasmid in
both infectivity and virulence in this model.
With regard to nvCT E/SW2, it was originally speculated
that the mutation of the plasmid in nvCT (E/SW2) was
responsible for amplification in the Swedish regional popu-
lation due to either a diagnostic or biological selective
advantage (Ripa & Nilsson, 2006); Unemo & Clarke, 2011).
Further, according to one large clinical study, women
infected with nvCT were less likely to exhibit symptomatic
urethral infection and lower abdominal pain (Bjartling et al.,
2009). Transmission was rare among those with more
international sexual networks such as heterosexuals in
higher ages and men who have sex with men (Unemo &
Clarke, 2011). Subsequently, no outstanding in vitro differ-
ences in nvCT were discerned by microscopy, growth
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kinetics, cell tropism, antimicrobial susceptibility, or inclusion
glycogen inclusion when compared to similar wild-type
isolates including, a serovar E C. trachomatis predominat-
ing in Sweden prior to the isolation of the mutant (Unemo
et al., 2010; Unemo & Clarke, 2011). Likewise, in these
studies, the genomic signature compared with other isolates
was unremarkable with no wholesale gene deletions or
substitutions. These results indicated that preponderance of
this isolate in many regions of Sweden was likely due to a
diagnostic selective advantage. Yet, fitness had heretofore
not been directly tested in vivo.
In the present study, mice infected with nvCT E/SW2
displayed some moderately reduced parameters of infectiv-
ity, but measures of virulence in the respiratory tract were
more equivocal. Overall, in vivo fitness appears reduced,
and thus these data do not support the mutant’s expansion
as a result of in vivo fitness and thus would more likely
support its expansion as a result of positive selective
pressure from diagnostic test avoidance.
Some caution should be exercised in interpreting our
present data. First of all, we carefully selected ser-
ovar-matched isolates that were predominating in the
human population at or before the time the F/SWFP or
plasmid mutant E/SW2 was initially isolated (Unemo &
Clarke, 2011). Genome sequencing has indicated that while
the chromosomes of the comparator strains differ on the
account of putative recombinations and SNPs, there were
no other whole gene differences. However, this was not
unexpected (Tables S1 and S2 (Unemo et al., 2010). This
analysis also showed how apparently closely matched,
cocirculating strains carry a number of SNPs, some in genes
putatively associated with virulence. It is not possible to
predict whether any of these SNPs contributed directly to
the differences we have observed in the mouse model.
However, our observations are quite consistent with the
aforementioned in vivo observations of plasmid-free strains
in human disease (Bjartling et al., 2009; Harris et al., 2012)
and in other animal models (O’Connell et al., 2007; Carlson
et al., 2008; Olivares-Zavaleta et al., 2010; Russell et al.,
2011). Thus, we feel the most logical inference is to attribute
the differences seen to presence and function of the
plasmid.
Secondly, C. trachomatis, unlike C. muridarum, is not a
natural pathogen of the mouse. Consequently, C. tracho-
matis infection induces neither the degree of infection
burden nor the pathology that is observed following C. mu-
ridarum urogenital or respiratory infections (Rank, 2006).
Thus, one should be mindful of these host and pathogen
differences when interpreting our data. Nonetheless, it is
pleasing that our findings largely support and agree with
those of others investigating the chlamydial plasmid in
mouse urogenital tract infections with LGV strains either
C. muridarum or C. trachomatis (O’Connell et al., 2007;
Carlson et al., 2008; Olivares-Zavaleta et al., 2010; Russell
et al., 2011). In the context of what has already been
reported by others regarding the chlamydial plasmid and
in vivo fitness, our results add to the growing body of
evidence that in many hosts and at specific anatomical sites,
the plasmid plays a role in modulating infectivity and
virulence, but this role is not universal. Now that a means
to genetically manipulate chlamydiae and selectively mutate
the plasmid has been elaborated and the function of the
plasmid can be dissected and studied in greater detail
(Wang et al., 2011; Song et al., 2013).
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